AL-335: Phase IIa started

Johnson & Johnson began an open-label Phase IIa trial to evaluate a once-daily oral regimen of Olysio/ Sovriad simeprevir, AL-335 and odalasvir ( ACH-3102) for 4, 6 or 8 weeks in about 60 patients. J&J’s Janssen Biotech Inc. unit has exclusive, worldwide rights to develop and commercialize HCV products and regimens containing >=1 HCV asset from Achillion Pharmaceuticals Inc. (NASDAQ:ACHN, New Haven, Conn.), including odalasvir (see BioCentury, May 25). Odalasvir is a pan-genotypic, second-generation HCV NS5A protein inhibitor. ...